Patent · US Active

Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity

US10662253B2 · kind B2 · utility

5Cited by

27References

6Claims

0Family size

Assignee

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR

Inventors

Yves Levy · Malakoff, FR
Jean-Francois Eliaou · Montpellier, FR
Armand Bensussan · Créteil, FR
Nathalie Bonnefoy-Berard · Créteil, FR

Key dates

Filing date	Nov 12, 2015
Grant date	May 26, 2020
Priority date	—
Expiry date	Nov 12, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.